Peptide-Based Drug Delivery System - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB511248646

Publication Date:

November 5, 2024

Pages:

110

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

A peptide-based drug delivery system refers to a technology or formulation that utilizes peptides to improve the delivery, targeting, and release of therapeutic drugs. These systems are designed to enhance the efficacy, bioavailability, and safety of drugs by specifically delivering them to the desired site of action in the body.
The global market for Peptide-Based Drug Delivery System was estimated to be worth US$ 32150 million in 2023 and is forecast to a readjusted size of US$ 43610 million by 2030 with a CAGR of 4.3% during the forecast period 2024-2030
Key market drivers for peptide-based drug delivery systems is the growing demand for targeted and personalized therapies. Peptides offer the advantage of high specificity and affinity for specific receptors or cell types, allowing for precise delivery of drugs to the desired sites in the body. This targeted approach enhances therapeutic efficacy while minimizing off-target effects and reducing systemic toxicity.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Peptide-Based Drug Delivery System, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Peptide-Based Drug Delivery System by region & country, by Type, and by Application.
The Peptide-Based Drug Delivery System market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide-Based Drug Delivery System.
Market Segmentation
By Company
Sanofi
Teva
Novo Nordisk
Takeda
Eli Lilly
AstraZeneca
Novartis
AbbVie
Ipsen
Ferring
Merck
The Medicines
Roche
J & J
Segment by Type:
Brand
Generic Drug
Segment by Application
Cancer
Metabolic Disorders
Central Nervous System
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Peptide-Based Drug Delivery System manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Peptide-Based Drug Delivery System in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Peptide-Based Drug Delivery System in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Market Overview
1.1 Peptide-Based Drug Delivery System Product Introduction
1.2 Global Peptide-Based Drug Delivery System Market Size Forecast
1.3 Peptide-Based Drug Delivery System Market Trends & Drivers
1.3.1 Peptide-Based Drug Delivery System Industry Trends
1.3.2 Peptide-Based Drug Delivery System Market Drivers & Opportunity
1.3.3 Peptide-Based Drug Delivery System Market Challenges
1.3.4 Peptide-Based Drug Delivery System Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Peptide-Based Drug Delivery System Players Revenue Ranking (2023)
2.2 Global Peptide-Based Drug Delivery System Revenue by Company (2019-2024)
2.3 Key Companies Peptide-Based Drug Delivery System Manufacturing Base Distribution and Headquarters
2.4 Key Companies Peptide-Based Drug Delivery System Product Offered
2.5 Key Companies Time to Begin Mass Production of Peptide-Based Drug Delivery System
2.6 Peptide-Based Drug Delivery System Market Competitive Analysis
2.6.1 Peptide-Based Drug Delivery System Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Peptide-Based Drug Delivery System Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide-Based Drug Delivery System as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Brand
3.1.2 Generic Drug
3.2 Global Peptide-Based Drug Delivery System Sales Value by Type
3.2.1 Global Peptide-Based Drug Delivery System Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Peptide-Based Drug Delivery System Sales Value, by Type (2019-2030)
3.2.3 Global Peptide-Based Drug Delivery System Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Cancer
4.1.2 Metabolic Disorders
4.1.3 Central Nervous System
4.1.4 Other
4.2 Global Peptide-Based Drug Delivery System Sales Value by Application
4.2.1 Global Peptide-Based Drug Delivery System Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Peptide-Based Drug Delivery System Sales Value, by Application (2019-2030)
4.2.3 Global Peptide-Based Drug Delivery System Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Peptide-Based Drug Delivery System Sales Value by Region
5.1.1 Global Peptide-Based Drug Delivery System Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Peptide-Based Drug Delivery System Sales Value by Region (2019-2024)
5.1.3 Global Peptide-Based Drug Delivery System Sales Value by Region (2025-2030)
5.1.4 Global Peptide-Based Drug Delivery System Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Peptide-Based Drug Delivery System Sales Value, 2019-2030
5.2.2 North America Peptide-Based Drug Delivery System Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Peptide-Based Drug Delivery System Sales Value, 2019-2030
5.3.2 Europe Peptide-Based Drug Delivery System Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Peptide-Based Drug Delivery System Sales Value, 2019-2030
5.4.2 Asia Pacific Peptide-Based Drug Delivery System Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Peptide-Based Drug Delivery System Sales Value, 2019-2030
5.5.2 South America Peptide-Based Drug Delivery System Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Peptide-Based Drug Delivery System Sales Value, 2019-2030
5.6.2 Middle East & Africa Peptide-Based Drug Delivery System Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Peptide-Based Drug Delivery System Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Peptide-Based Drug Delivery System Sales Value
6.3 United States
6.3.1 United States Peptide-Based Drug Delivery System Sales Value, 2019-2030
6.3.2 United States Peptide-Based Drug Delivery System Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Peptide-Based Drug Delivery System Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Peptide-Based Drug Delivery System Sales Value, 2019-2030
6.4.2 Europe Peptide-Based Drug Delivery System Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Peptide-Based Drug Delivery System Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Peptide-Based Drug Delivery System Sales Value, 2019-2030
6.5.2 China Peptide-Based Drug Delivery System Sales Value by Type (%), 2023 VS 2030
6.5.3 China Peptide-Based Drug Delivery System Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Peptide-Based Drug Delivery System Sales Value, 2019-2030
6.6.2 Japan Peptide-Based Drug Delivery System Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Peptide-Based Drug Delivery System Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Peptide-Based Drug Delivery System Sales Value, 2019-2030
6.7.2 South Korea Peptide-Based Drug Delivery System Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Peptide-Based Drug Delivery System Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Peptide-Based Drug Delivery System Sales Value, 2019-2030
6.8.2 Southeast Asia Peptide-Based Drug Delivery System Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Peptide-Based Drug Delivery System Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Peptide-Based Drug Delivery System Sales Value, 2019-2030
6.9.2 India Peptide-Based Drug Delivery System Sales Value by Type (%), 2023 VS 2030
6.9.3 India Peptide-Based Drug Delivery System Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Sanofi
7.1.1 Sanofi Profile
7.1.2 Sanofi Main Business
7.1.3 Sanofi Peptide-Based Drug Delivery System Products, Services and Solutions
7.1.4 Sanofi Peptide-Based Drug Delivery System Revenue (US$ Million) & (2019-2024)
7.1.5 Sanofi Recent Developments
7.2 Teva
7.2.1 Teva Profile
7.2.2 Teva Main Business
7.2.3 Teva Peptide-Based Drug Delivery System Products, Services and Solutions
7.2.4 Teva Peptide-Based Drug Delivery System Revenue (US$ Million) & (2019-2024)
7.2.5 Teva Recent Developments
7.3 Novo Nordisk
7.3.1 Novo Nordisk Profile
7.3.2 Novo Nordisk Main Business
7.3.3 Novo Nordisk Peptide-Based Drug Delivery System Products, Services and Solutions
7.3.4 Novo Nordisk Peptide-Based Drug Delivery System Revenue (US$ Million) & (2019-2024)
7.3.5 Takeda Recent Developments
7.4 Takeda
7.4.1 Takeda Profile
7.4.2 Takeda Main Business
7.4.3 Takeda Peptide-Based Drug Delivery System Products, Services and Solutions
7.4.4 Takeda Peptide-Based Drug Delivery System Revenue (US$ Million) & (2019-2024)
7.4.5 Takeda Recent Developments
7.5 Eli Lilly
7.5.1 Eli Lilly Profile
7.5.2 Eli Lilly Main Business
7.5.3 Eli Lilly Peptide-Based Drug Delivery System Products, Services and Solutions
7.5.4 Eli Lilly Peptide-Based Drug Delivery System Revenue (US$ Million) & (2019-2024)
7.5.5 Eli Lilly Recent Developments
7.6 AstraZeneca
7.6.1 AstraZeneca Profile
7.6.2 AstraZeneca Main Business
7.6.3 AstraZeneca Peptide-Based Drug Delivery System Products, Services and Solutions
7.6.4 AstraZeneca Peptide-Based Drug Delivery System Revenue (US$ Million) & (2019-2024)
7.6.5 AstraZeneca Recent Developments
7.7 Novartis
7.7.1 Novartis Profile
7.7.2 Novartis Main Business
7.7.3 Novartis Peptide-Based Drug Delivery System Products, Services and Solutions
7.7.4 Novartis Peptide-Based Drug Delivery System Revenue (US$ Million) & (2019-2024)
7.7.5 Novartis Recent Developments
7.8 AbbVie
7.8.1 AbbVie Profile
7.8.2 AbbVie Main Business
7.8.3 AbbVie Peptide-Based Drug Delivery System Products, Services and Solutions
7.8.4 AbbVie Peptide-Based Drug Delivery System Revenue (US$ Million) & (2019-2024)
7.8.5 AbbVie Recent Developments
7.9 Ipsen
7.9.1 Ipsen Profile
7.9.2 Ipsen Main Business
7.9.3 Ipsen Peptide-Based Drug Delivery System Products, Services and Solutions
7.9.4 Ipsen Peptide-Based Drug Delivery System Revenue (US$ Million) & (2019-2024)
7.9.5 Ipsen Recent Developments
7.10 Ferring
7.10.1 Ferring Profile
7.10.2 Ferring Main Business
7.10.3 Ferring Peptide-Based Drug Delivery System Products, Services and Solutions
7.10.4 Ferring Peptide-Based Drug Delivery System Revenue (US$ Million) & (2019-2024)
7.10.5 Ferring Recent Developments
7.11 Merck
7.11.1 Merck Profile
7.11.2 Merck Main Business
7.11.3 Merck Peptide-Based Drug Delivery System Products, Services and Solutions
7.11.4 Merck Peptide-Based Drug Delivery System Revenue (US$ Million) & (2019-2024)
7.11.5 Merck Recent Developments
7.12 The Medicines
7.12.1 The Medicines Profile
7.12.2 The Medicines Main Business
7.12.3 The Medicines Peptide-Based Drug Delivery System Products, Services and Solutions
7.12.4 The Medicines Peptide-Based Drug Delivery System Revenue (US$ Million) & (2019-2024)
7.12.5 The Medicines Recent Developments
7.13 Roche
7.13.1 Roche Profile
7.13.2 Roche Main Business
7.13.3 Roche Peptide-Based Drug Delivery System Products, Services and Solutions
7.13.4 Roche Peptide-Based Drug Delivery System Revenue (US$ Million) & (2019-2024)
7.13.5 Roche Recent Developments
7.14 J & J
7.14.1 J & J Profile
7.14.2 J & J Main Business
7.14.3 J & J Peptide-Based Drug Delivery System Products, Services and Solutions
7.14.4 J & J Peptide-Based Drug Delivery System Revenue (US$ Million) & (2019-2024)
7.14.5 J & J Recent Developments
8 Industry Chain Analysis
8.1 Peptide-Based Drug Delivery System Industrial Chain
8.2 Peptide-Based Drug Delivery System Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Peptide-Based Drug Delivery System Sales Model
8.5.2 Sales Channel
8.5.3 Peptide-Based Drug Delivery System Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Sanofi
Teva
Novo Nordisk
Takeda
Eli Lilly
AstraZeneca
Novartis
AbbVie
Ipsen
Ferring
Merck
The Medicines
Roche
J & J

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂